-
Product Insights
New![]()
Innovation in pharma: small molecule kinase inhibitors
Why settle for outdated information when you can stay ahead of the curve with our comprehensive report? Our team of industry experts has meticulously researched and analyzed the latest trends, innovations, and emerging technologies in the pharma industry’s small molecule kinase inhibitors innovations. By leveraging our report, you'll gain invaluable insights that can revolutionize your business strategies and give you a competitive edge. Why Choose Our Report? Unparalleled Expertise: Our research team consists of seasoned analysts with deep knowledge and...
-
Product Insights
Central Small Field, India
Central Small upstream field is located in Assam, India. The upstream field is owned by Oil India Ltd. It is operated by Oil India Ltd. The project started its operations in 1995. Central Small Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and end years, reserves and capital and operating costs. We also provide...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cellular Immunotherapy For Non-Small Cell Lung Cancer in Non-Small Cell Lung Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cellular Immunotherapy For Non-Small Cell Lung Cancer in Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cellular Immunotherapy for Non-Small Cell Lung Cancer in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Cellular Immunotherapy For Non-Small Cell Lung Cancer in Non-Small Cell Lung Cancer Drug Details:Cellular immunotherapy is...
-
Product Insights
Karim small fields Field, Oman
Karim small fields is located in Al Wusta, Oman. The upstream field is owned by Medco LLC (75%); Oman Oil Company Exploration & Production LLC (25%). It is operated by Medco LLC. The project started its operations in 2000. Karim small fields Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and end years, reserves...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Target Egfr For Non Small Cell Lung Cancer in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Gene Therapy To Target Egfr For Non Small Cell Lung Cancer in Non-Small Cell Lung CancerDrug...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ivonescimab in Small-Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ivonescimab in Small-Cell Lung Cancer Drug Details: Ivonescimab (AK-112) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cadonilimab in Small-Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cadonilimab in Small-Cell Lung Cancer Drug Details: Cardinalizumab (Ketanil) is a bi-specific antibody acts as...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Dostarlimab in Small-Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Dostarlimab in Small-Cell Lung Cancer Drug Details: Dostarlimab (Jemperli) is a immunoglobulin G4 humanized monoclonal...
-
Product Insights
Rima Cluster of Small Fields Field, Oman
Rima Cluster of Small Fields is located in Al Wusta, Oman. The upstream field is owned by Oman Oil Company Exploration & Production LLC (25%); Petrogas Rima LLC (75%). It is operated by Petrogas Rima LLC. The project started its operations in 1982. Rima Cluster of Small Fields Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cosibelimab in Small-Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Cosibelimab in Small-Cell Lung Cancer Drug Details: Cosibelimab is under development for the treatment of hematological...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ezobresib in Small-Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Ezobresib in Small-Cell Lung Cancer Drug Details: Ezobresib (BMS-986158) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ociperlimab in Small-Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Ociperlimab in Small-Cell Lung Cancer Drug Details: Ociperlimab (BGB-A1217) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Magrolimab in Small-Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Magrolimab in Small-Cell Lung Cancer Drug Details: Magrolimab is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tislelizumab in Small-Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tislelizumab in Small-Cell Lung Cancer Drug Details: Tislelizumab (Baizean) is a humanized monoclonal antibody that...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Glecirasib in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Glecirasib in Non-Small Cell Lung Cancer Drug Details: Glecirasib (JAB-21000) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – A-400 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. A-400 in Non-Small Cell Lung Cancer Drug Details: KL-590586 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Iparomlimab + Tuvonralimab in Small-Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Iparomlimab + Tuvonralimab in Small-Cell Lung Cancer Drug Details: Tuvonralimab (PSB-205) in combination with iparomlimab is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cadonilimab in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cadonilimab in Non-Small Cell Lung Cancer Drug Details: Cardinalizumab (Ketanil) is a bi-specific antibody acts...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Nemvaleukin Alfa in Small-Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nemvaleukin Alfa in Small-Cell Lung Cancer Drug Details: Nemvaleukin alfa (ALKS-4230) is under development for...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.